Mirtazapina Sandoz Bv (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which raises norepinephrine and serotonin release. It also antagonises 5‑HT2 and 5‑HT3 receptors while acting as a 5‑HT1A agonist, enhancing serotonergic transmission and contributing to its antidepressant and sedative effects.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage may be started at a low level and titrated upward, but exact regimens should follow the prescriber’s instructions and local labeling.

Safety data for mirtazapine in pregnancy and lactation are limited, and the medication is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, whereas SSRIs primarily inhibit serotonin reuptake. Mirtazapine often causes sedation and weight gain, which can be advantageous for patients with insomnia or loss of appetite, while SSRIs are generally more activating and have a different side‑effect profile. Choice depends on individual symptom patterns and tolerability.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Mirtazapina Sandoz Bv is taken orally, usually once daily in the evening with or without food, as directed by the prescribing clinician. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious adverse events include agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for signs of infection, skin reactions, or changes in mood.

Mirtazapine should be avoided in individuals with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or patients with severe hepatic impairment without dose adjustment. Caution is also advised for patients with uncontrolled cardiovascular disease or a history of seizures.